Doney K, Storb R, Appelbaum F R, Buckner C D, Sanders J, Singer J, Hansen J A
Fred Hutchinson Cancer Research Center, Veterans Affairs Medical Center, Seattle, Washington 98104.
Br J Haematol. 1993 Sep;85(1):182-4. doi: 10.1111/j.1365-2141.1993.tb08665.x.
Seventeen patients with aplastic anaemia were treated with recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) for 14 d. Nonresponding patients were then treated with anti-human thymocyte globulin (ATG), methylprednisolone and oxymetholone. Side-effects of rhGM-CSF included fever, nausea and vomiting, diarrhoea, bone pain, headache and chills. Two patients had sustained trilineage haemopoietic recovery after receiving only rhGM-CSF. Of 11 patients who received immunosuppressive therapy, there was one complete response, two partial responses, one minimal response, and seven nonresponses. Actuarial survival at 2 years is 64%. Early administration of rhGM-CSF had no apparent effect on subsequent response to immunosuppressive therapy.
17例再生障碍性贫血患者接受重组人粒细胞巨噬细胞集落刺激因子（rhGM-CSF）治疗14天。无反应的患者随后接受抗人胸腺细胞球蛋白（ATG）、甲泼尼龙和羟甲烯龙治疗。rhGM-CSF的副作用包括发热、恶心、呕吐、腹泻、骨痛、头痛和寒战。2例患者仅接受rhGM-CSF治疗后出现三系造血持续恢复。在接受免疫抑制治疗的11例患者中，1例完全缓解，2例部分缓解，1例微小缓解，7例无反应。2年的精算生存率为64%。早期给予rhGM-CSF对随后的免疫抑制治疗反应无明显影响。
